Sale!

CYP3A4*22 Genotyping Test Cost

Original price was: 1,660 د.إ.Current price is: 1,500 د.إ.

-10%

The CYP3A4*22 Genotyping Test is a specialized diagnostic tool designed to analyze the CYP3A4 gene, specifically the *22 allele, to predict an individual’s response to various medications. This test is crucial because the CYP3A4 enzyme is responsible for metabolizing approximately half of all drugs in the market, including statins, antipsychotics, and several cancer medications. Variations in the CYP3A4 gene, such as the *22 allele, can significantly affect drug metabolism, leading to either suboptimal drug efficacy or increased risk of adverse drug reactions.

Performed at DNA Labs UAE, the test aims to provide personalized medication guidance based on genetic makeup. By identifying whether an individual has the CYP3A4*22 variant, healthcare providers can adjust drug dosages or choose alternative medications, enhancing treatment effectiveness and safety.

The cost of the CYP3A4*22 Genotyping Test at DNA Labs UAE is 1500 AED. This investment in personalized medicine not only contributes to more tailored healthcare strategies but also minimizes the trial-and-error approach often associated with prescribing medications, offering a more efficient and patient-centered approach to medical treatment.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

CYP3A4*22 GENOTYPING Test

Components

Price: 1500.0 AED

Sample Condition: 4 mL (2 mL min.) whole blood in 1 Lavender top (EDTA) tube. Ship refrigerated. DO NOT FREEZE.

Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory.

Report Delivery

Sample Sat by 11 am; Report 10 Working days

Method

PCR, Sequencing

Test type

Pharmacogenomics

Doctor

Physician

Test Department

MOLECULAR DIAGNOSTICS

Pre Test Information

Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory.

Test Details

The CYP3A4*22 genotyping test is a genetic test that determines the presence of a specific variant in the CYP3A4 gene called CYP3A4*22. This variant is associated with reduced activity of the CYP3A4 enzyme, which is responsible for metabolizing many drugs in the body.

The test is typically performed using a blood or saliva sample. The sample is analyzed in a laboratory to detect the presence of the CYP3A4*22 variant.

The results of the test can help healthcare providers personalize drug dosages and select appropriate medications for individuals with this genetic variant.

CYP3A4*22 genotyping may be recommended in certain situations, such as when an individual experiences unexpected side effects or poor response to medications that are metabolized by the CYP3A4 enzyme.

It can also be useful in predicting drug interactions and determining optimal drug dosages for individuals with the CYP3A4*22 variant.

It is important to note that the CYP3A4*22 genotyping test is just one tool that healthcare providers can use to guide treatment decisions. Other factors, such as a person’s medical history and other genetic variations, should also be taken into consideration when determining the most appropriate treatment approach.

Test Name CYP3A4*22 GENOTYPING Test
Components
Price 1500.0 AED
Sample Condition 4 mL (2 mL min.) whole blood in 1 Lavender top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory.
Report Delivery Sample Sat by 11 am;Report 10 Working days
Method PCR, Sequencing
Test type Pharmacogenomics
Doctor Physician
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information Duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory.
Test Details

The CYP3A4*22 genotyping test is a genetic test that determines the presence of a specific variant in the CYP3A4 gene called CYP3A4*22. This variant is associated with reduced activity of the CYP3A4 enzyme, which is responsible for metabolizing many drugs in the body.

The test is typically performed using a blood or saliva sample. The sample is analyzed in a laboratory to detect the presence of the CYP3A4*22 variant. The results of the test can help healthcare providers personalize drug dosages and select appropriate medications for individuals with this genetic variant.

CYP3A4*22 genotyping may be recommended in certain situations, such as when an individual experiences unexpected side effects or poor response to medications that are metabolized by the CYP3A4 enzyme. It can also be useful in predicting drug interactions and determining optimal drug dosages for individuals with the CYP3A4*22 variant.

It is important to note that the CYP3A4*22 genotyping test is just one tool that healthcare providers can use to guide treatment decisions. Other factors, such as a person’s medical history and other genetic variations, should also be taken into consideration when determining the most appropriate treatment approach.